243 related articles for article (PubMed ID: 3426872)
21. Vaccine production as a unit process.
van Hemert P
Prog Ind Microbiol; 1974; 13():151-271. PubMed ID: 4373785
[No Abstract] [Full Text] [Related]
22. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
Carrada Bravo T
Rev Alerg; 1993; 40(4):91-4. PubMed ID: 8143024
[TBL] [Abstract][Full Text] [Related]
23. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.
Albert MJ; Alam K; Ansaruzzaman M; Qadri F; Sack RB
J Infect Dis; 1994 Jan; 169(1):230-1. PubMed ID: 8277193
[No Abstract] [Full Text] [Related]
24. The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine.
Provenzano D; Kovác P; Wade WF
Microbiol Immunol; 2006; 50(12):899-927. PubMed ID: 17179659
[TBL] [Abstract][Full Text] [Related]
25. The development of a bivalent vaccine against diarrhoeal disease.
Forrest BD
Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):449-57. PubMed ID: 2464195
[TBL] [Abstract][Full Text] [Related]
26. Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen.
Attridge SR; Dearlove C; Beyer L; van den Bosch L; Howles A; Hackett J; Morona R; LaBrooy J; Rowley D
Infect Immun; 1991 Jul; 59(7):2279-84. PubMed ID: 1711014
[TBL] [Abstract][Full Text] [Related]
27. Non-O1 Vibrio cholerae and epidemic cholera.
Commun Dis Rep CDR Wkly; 1993 Jun; 3(24):107. PubMed ID: 7693194
[No Abstract] [Full Text] [Related]
28. [The prospects for improving chemical cholera vaccines].
Markov EIu; Maramovich AS; Golubinskiĭ EP; Urbanovich LIa
Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):91-6. PubMed ID: 9783412
[No Abstract] [Full Text] [Related]
29. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
Stewart-Tull DE; Lucas C; Bleakley CR
Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
[TBL] [Abstract][Full Text] [Related]
30. Five-year immunologic memory in Swedish volunteers after oral cholera vaccination.
Jertborn M; Svennerholm AM; Holmgren J
J Infect Dis; 1988 Feb; 157(2):374-7. PubMed ID: 3335813
[No Abstract] [Full Text] [Related]
31. [The immunology of cholera and the molecular biology of cholera toxin. Recent progress and future perspectives].
Carrada-Bravo T
Rev Alerg Mex; 1994; 41(3):69-76. PubMed ID: 9377108
[TBL] [Abstract][Full Text] [Related]
32. Cholera as a model for research on mucosal immunity and development of oral vaccines.
Holmgren J; Czerkinsky C
Curr Opin Immunol; 1992 Aug; 4(4):387-91. PubMed ID: 1388838
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
34. Impairment of immunogenicity of Salmonella typhi Ty21a due to preexisting cross-reacting intestinal antibodies.
Forrest BD
J Infect Dis; 1992 Jul; 166(1):210-12. PubMed ID: 1607701
[No Abstract] [Full Text] [Related]
35. [The mucosa immune system and immunization by intestinal infections].
Deicher H
Z Gastroenterol Verh; 1978; (14):37-47. PubMed ID: 88841
[No Abstract] [Full Text] [Related]
36. Compatible concurrent administration of yellow fever 17D vaccine with oral, live, attenuated p6olera CVD103-HgR and typhoid ty21a vaccines.
Tsai TF; Kollaritsch H; Que JU; Cropp CB; Kunz C; Wiedermann G; Herzog C; Cryz SJ
J Infect Dis; 1999 Feb; 179(2):522-4. PubMed ID: 9878043
[No Abstract] [Full Text] [Related]
37. Editorial Commentary: Resurrecting a Live Oral Cholera Vaccine.
Harris JB
Clin Infect Dis; 2016 Jun; 62(11):1336-7. PubMed ID: 27001802
[No Abstract] [Full Text] [Related]
38. Local and systemic immunity after typhoid vaccines.
Tagliabue A; Villa L; Boraschi D; Nencioni L
Ann Sclavo Collana Monogr; 1986; 3(1-2):31-9. PubMed ID: 3322341
[No Abstract] [Full Text] [Related]
39. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
[TBL] [Abstract][Full Text] [Related]
40. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses.
Yang JS; Kim HJ; Yun CH; Kang SS; Im J; Kim HS; Han SH
J Microbiol Methods; 2007 Nov; 71(2):141-6. PubMed ID: 17888533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
